Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis
作者:Ann L. Walker、Nicolas Ancellin、Benjamin Beaufils、Marylise Bergeal、Margaret Binnie、Anne Bouillot、David Clapham、Alexis Denis、Carl P. Haslam、Duncan S. Holmes、Jonathan P. Hutchinson、John Liddle、Andrew McBride、Olivier Mirguet、Christopher G. Mowat、Paul Rowland、Nathalie Tiberghien、Lionel Trottet、Iain Uings、Scott P. Webster、Xiaozhong Zheng、Damian J. Mole
DOI:10.1021/acs.jmedchem.7b00055
日期:2017.4.27
Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments for neurodegenerative conditions and particularly for Huntington’s disease. However, the inhibitors reported to date have insufficient aqueous solubility relative to their cellular potency to be compatible
This paper describes the preparation of a new chiral building block containing a benzylic quaternary stereogenic center via the highly enantioselective PLE-mediated hydrolysis of dimethyl 2-(2-chloro-5-methoxyphenyl)-2-methylmalonate, as well as the absolute configuration of the new chiral building block, which has been elucidated through the formaltotalsynthesis of (−)-physostigmine.